RxSight, Inc. (NASDAQ:RXST) Holdings Reduced by Squarepoint Ops LLC

Squarepoint Ops LLC lessened its holdings in shares of RxSight, Inc. (NASDAQ:RXST) by 10.5% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 98,040 shares of the company’s stock after selling 11,447 shares during the quarter. Squarepoint Ops LLC’s holdings in RxSight were worth $5,899,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. CWM LLC raised its stake in RxSight by 727.5% during the 2nd quarter. CWM LLC now owns 422 shares of the company’s stock valued at $25,000 after acquiring an additional 371 shares in the last quarter. Quest Partners LLC acquired a new position in shares of RxSight during the second quarter valued at $41,000. Larson Financial Group LLC bought a new stake in shares of RxSight during the first quarter valued at about $51,000. Amalgamated Bank lifted its holdings in RxSight by 21.3% in the second quarter. Amalgamated Bank now owns 1,177 shares of the company’s stock worth $71,000 after purchasing an additional 207 shares during the period. Finally, Canada Pension Plan Investment Board bought a new position in RxSight in the 2nd quarter valued at about $156,000. 78.78% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have commented on RXST. Oppenheimer dropped their price target on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 6th. Wells Fargo & Company dropped their target price on RxSight from $68.00 to $54.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. Needham & Company LLC reaffirmed a “buy” rating and set a $66.00 price target on shares of RxSight in a research note on Friday, September 13th. Stifel Nicolaus lowered their price target on RxSight from $70.00 to $65.00 and set a “buy” rating on the stock in a research report on Tuesday, August 6th. Finally, BTIG Research upped their price objective on RxSight from $72.00 to $73.00 and gave the company a “buy” rating in a report on Monday, July 15th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $60.14.

RxSight Stock Performance

Shares of NASDAQ:RXST opened at $48.54 on Monday. The stock has a fifty day moving average of $51.15 and a 200-day moving average of $53.88. The company has a market capitalization of $1.80 billion, a PE ratio of -38.52 and a beta of 1.22. RxSight, Inc. has a one year low of $20.66 and a one year high of $66.54.

RxSight (NASDAQ:RXST) last posted its quarterly earnings data on Monday, August 5th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.06. The company had revenue of $34.89 million during the quarter, compared to analyst estimates of $32.33 million. RxSight had a negative net margin of 31.92% and a negative return on equity of 19.33%. The business’s quarterly revenue was up 67.6% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.40) earnings per share. As a group, research analysts forecast that RxSight, Inc. will post -0.81 EPS for the current fiscal year.

Insider Buying and Selling

In other RxSight news, insider Ilya Goldshleger sold 3,100 shares of the business’s stock in a transaction on Friday, September 20th. The shares were sold at an average price of $53.19, for a total transaction of $164,889.00. Following the sale, the insider now directly owns 42,246 shares of the company’s stock, valued at approximately $2,247,064.74. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In the last 90 days, insiders sold 15,200 shares of company stock valued at $681,416. Company insiders own 9.36% of the company’s stock.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.